Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

This trial is comparing two treatment options — lurbinectedin (alone or with irinotecan) versus topotecan — for people with small cell lung cancer (SCLC) that has come back after initial treatment. **You may be eligible if...** - You are 18 or older with confirmed small cell lung cancer - Your cancer has returned after one prior treatment regimen with etoposide and a platinum drug (with or without immunotherapy) - You are in reasonably good physical condition (ECOG 0–2) - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have received more than one prior line of treatment for SCLC - You have uncontrolled brain metastases - You have severe bone marrow, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.